Special Issue

Carbon Nanomaterials in Pharmaceutical Sciences: Exploring Antibacterial, Antiviral, and Anticancer Properties

Message from the Guest Editor

Carbon nanomaterials comprise a novel class of materials with unique properties that can provide information about the health of certain cells, tissues, and organs: they accumulate in the target tissue/organ, perform desired and controlled treatments, inform us about the course of treatment, and are finally eliminated from the body without side effects. Multifaceted treatments for infectious diseases or cancer using one or more carbon nanomaterials can provide a platform for personalized medicine.

Almost 40 years have passed since the discovery of the first carbon nanomaterial. In the meantime, novel carbon nanomaterials such as carbon nanotubes, nanodiamonds, graphene, and carbon quantum dots have been produced. Although carbon nanomaterials have numerous advantages over existing drugs in the treatment of diseases, their application is still at a very low level. The main obstacles to their widespread application are their price, efficiency, and toxicity. Therefore, it is very important to study the biomedical applications of carbon nanomaterials, as well as the mechanisms of direct/indirect interaction between carbon nanomaterials and simple and complex cells and tissues.

Guest Editor

Prof. Dr. Zoran M. Marković

Vinča Institute of Nuclear Sciences—National Institute of the Republic of Serbia, University of Belgrade, P.O. Box 522, 11000 Belgrade, Serbia

Deadline for manuscript submissions

10 May 2026



an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/204512

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, New Jersey 08854-8020, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

